- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06199479
Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objectives To determine if advanced imaging findings can correlate with tissue changes in order to distinguish true progression from pseudoprogression. We will recruit participants with new suspicious enhancement developing during treatment for glioma, and systematically perform: a) high quality routine MR imaging (including routine, diffusion, permeability, perfusion and spectroscopy imaging as part of our regular ABTI protocol) and compare this imaging to b) pathology obtained by means of stereotactic biopsy. Pathology will serve as the gold standard to determine which imaging strategies are most successful in distinguishing between true Tumor recurrence and Pseudoprogression for each lesion.
Secondary Objectives
- To assess the feasibility of Contrast Clearance MR (delayed T1 enhanced MR) subtraction maps in distinguishing Pseudoprogression from true progression.
- To gather observational data for Dual Energy CT imaging and delayed contrast clearance with Dual Energy CT in the assessment of glioma.
- To correlate quantitative imaging biomarkers (derived from MR imaging data) along the biopsy tract with histological and clinical biomarkers. This exploratory data could generate novel comparisons to determine those imaging biomarkers that are most effective at predicting (a) cellular density and, (b) the types and relative numbers of cells present in the brain.
- To observe clinical outcomes such as progression free survival and overall survival in the trial population and relate these to imaging findings.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Dawid Schellingerhout, MD
- Phone Number: (713) 794-5673
- Email: dawid.schellingerhout@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
Contact:
- Dawid Schellingerhout, MD
- Phone Number: 713-794-5673
- Email: dawid.schellingerhout@mdanderson.org
-
Principal Investigator:
- Dawid Schellingerhout, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants is >18 years old. The pediatric population has a different disease profile from adult glioma participants. To reduce heterogeneity in the patient population we will not consider participants younger than 18 for this study.
- The participants agrees to participate in the clinical study and to complete all required visits and evaluations.
- Participants has undergone prior treatment for a brain tumor and has a new suspicious imaging finding requiring diagnostic workup and is being considered for biopsy.
- Participants agrees to undergo, prior to the procedure, the needed imaging evaluation (within 14 days and preferably with 3 days of the planned procedure).
Exclusion Criteria:
- Renal failure as evidenced by a GFR of less than 30 mL/min/1.73m2 for gadolinium based imaging. In the absence of eGFR lab result, participants is not excluded in the absence of remarkable pathological renal history, as confirmed by and in the discretion of the PI.
- For iodinated contrast agent we will use the more strict cut-off of 45 mL/min/1.73m2 ((Davenport, Perazella et al. 2020), Consensus statement from the ACR and the National Kidney Foundation). The different threshold reflects the different risk profiles of these agents. Participants with GFR in the range 30-45 can receive a Non-Contrast DECT (CT contrast withheld).
Pacemakers, electronic stimulation, metallic foreign bodies and devices and/or other conditions that are not MR safe, which include but are not limited to:
- electronically, magnetically, and mechanically activated implants
- ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators and cardiac pacemakers
- metallic splinters in the eye
- ferromagnetic hemostatic clips in the central nervous system (CNS) or body
- cochlear implants
- other pacemakers, e.g., for the carotid sinus
- insulin pumps and nerve stimulators
- non-MR safe lead wires
- prosthetic heart valves (if dehiscence is suspected)
- non-ferromagnetic stapedial implants
- pregnancy
- claustrophobia that does not readily respond to oral medication.
- Allergy to relevant imaging contrast agents, includes allergies to iodine or gadolinium-based contrast agents (if one class of agents is contra-indicated, then imaging with the other can still proceed).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Arm 1
The tests and procedures done as part of your standard-of-care biopsy preparation, participants will also have advanced MRI and CT scans performed no later than 2 weeks before the biopsy.
Typically, these scans are done within 1 or 2 days before surgery to provide the most accurate images to the surgeon.
|
Performed by MRI Scan
Performed by CT Scan
Standard of Care Biopsy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and adverse events (AEs)
Time Frame: Through study completion; an average of 1 year
|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
|
Through study completion; an average of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dawid Schellingerhout, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-0671
- NCI-2023-11127 (Other Identifier: NCI-CTRP Clinical Registry)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Malignancies
-
Sheba Medical CenterAssaf-Harofeh Medical CenterTerminatedBRAIN MALIGNANCIES AFTER RADIATION THERAPYIsrael
-
Amsterdam UMC, location VUmcCompletedColorectum Advanced Malignancies | Breast Advanced Malignancies | Prostate Advanced MalignanciesNetherlands
-
National University Hospital, SingaporeRecruitingMetastatic Solid Malignancies | Advance Solid MalignanciesSingapore
-
AHS Cancer Control AlbertaCross Cancer InstituteWithdrawnMetastatic Solid Malignancies | Locally Advanced Solid MalignanciesCanada
-
Kiromic, Inc.TerminatedCancer | Progressive Solid Malignancies | Refractory Solid MalignanciesUnited States
-
Curon Biopharmaceutical (Australia) Co Pty LtdNovotech (Australia) Pty LimitedTerminatedRelapsed Lymphoid Malignancies | Refractory Lymphoid MalignanciesAustralia
-
Cristina GasparettoAgilent Technologies, Inc.Active, not recruitingLymphoid Malignancies | Myeloid MalignanciesUnited States
-
Ospedale Santa Croce-Carle CuneoUnknownAdvanced Haematological Malignancies | High Risk Haematological MalignanciesItaly
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingTotal Exenteration | Anterior or Posterior Pelvic Exenteration | Gynecologic Malignancies | Colorectal Malignancies | Urologic MalignanciesUnited States
-
Massachusetts General HospitalActive, not recruitingBrain Tumors | Non-CNS MalignanciesUnited States
Clinical Trials on MRI Scan
-
University of ChicagoRecruitingBreast CancerUnited States
-
Jeffrey A. Lieberman, MDTerminated
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)TerminatedSchizophreniaUnited States
-
Radboud University Medical CenterCompletedHead and Neck NeoplasmsNetherlands
-
The Clatterbridge Cancer Centre NHS Foundation...Unknown
-
University of LeicesterNational Institute for Health Research, United KingdomCompletedPatients With Heart Failure and Preserved Ejection Fraction - HFpEF | Patients With Heart Failure With Reduced Ejection Fraction - HFrEF | Healthy Controls Group - Age and Sex-matched
-
Amsterdam UMC, location VUmcMRIguidance B.V.CompletedSinusitis | Hearing Loss | Head and Neck Tumor | Cholesteatoma | Imaging of Bony Structures of the Head (Various Conditions)Netherlands
-
University Hospitals Bristol and Weston NHS Foundation...Bosum Buddies; Friends of the Bristol Haematology and Oncology CentreTerminated
-
West China HospitalRecruiting
-
Imperial College LondonRecruitingDiastolic DysfunctionUnited Kingdom